Topics

FDA developing new guidance on opioid risk-benefit assessments

06:07 EDT 28 Jun 2019 | SmartBrief

The FDA is developing new draft guidance related to opioid risk-benefit assessments that will require opioid drug sponsors to -More

Original Article: FDA developing new guidance on opioid risk-benefit assessments

NEXT ARTICLE

More From BioPortfolio on "FDA developing new guidance on opioid risk-benefit assessments"

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...